RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated oncogene
family in human cancer. With the highest RAS mutation frequencies seen with the top three …

Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …

B cell receptor (BCR) signalling has emerged as a therapeutic target in B cell lymphomas,
but inhibiting this pathway in diffuse large B cell lymphoma (DLBCL) has benefited only a …

Nucleic acids are a promising type of therapeutic for the treatment of a wide range of
conditions, including cancer, but they also pose many delivery challenges. For efficient and …

Early detection and treatment of disease is the most important component of a favorable
prognosis. Biomedical researchers have thus invested tremendous effort in improving …

Binding within or nearby target genes involved in cell proliferation and survival enables the
p53 tumor suppressor gene to regulate their transcription and cell-cycle progression. Using …

Although thousands of long noncoding RNAs (lncRNAs) have been discovered, very little is
known about their mode of action. Here we functionally characterize an E2F1-regulated …

Genome-wide genetic approaches have proven useful for examining pathways of biological
significance in model organisms such as Saccharomyces cerevisiae, Drosophila …

The three-dimensional culture of MCF-10A mammary epithelial cells on a reconstituted
basement membrane results in formation of polarized, growth-arrested acini-like spheroids …

The discovery that gene expression can be controlled by the Watson–Crick base-pairing of
small RNAs with messenger RNAs containing complementary sequence—a process known …